FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
- 33
FIT Biotech Oy
Company release May 25, 2018 at 3:30 PM EET
Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
Related to Convertible Note and Warrant Programmes established on December 22, 2017 between the FIT Biotech Oy ("Company") and Alpha Blue Ocean ("ABO") the Company's Board of Directors have resolved on May 25, 2018 to approve ABO's request relating to the funding programme to convert EUR 75,000 worth of Convertible Capital Notes into the Company's K shares.
Due to the conversion of the Convertible Capital Notes, the Company transfers 150,000,000 K shares owned by the Company to ABO with the conversion price of EUR 0.0005 per share and the reserve for invested unrestricted equity of the Company will be increased by EUR 75,000.00. The Board authorization is based on General Meeting April 12, 2018.
The Company holds 1,001,924,221 K shares in treasury after the delivery of these shares.
The K shares will be admitted to trading on First North Finland on or about May 30, 2018.
After this transaction, FIT Biotech Oy has listed shares amounting to 1,907,307,467 K shares.
FIT BIOTECH OY
Board of Directors
For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
E-mail: [email protected]
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: FIT Biotech Oy via Globenewswire
GlobeNewswire Europe, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
- UAB Partnerystės projektai keturi 2023 audited annual report
- Ørsted to present Q1 2024 results on 2 May
- EQS-News: Asklepios Group: Asklepios shows resilience in 2023 financial year
- EQS-News: Nabaltec AG with a dividend proposal of EUR 0.28 per share and revenues of EUR 54.0 million in the first quarter of 2024 according to preliminary figures
- Share Buyback Transaction Details April 18 – April 24, 2024
- Trakx launches a new product: Trakx USDc Earn CTI powered by OpenTrade